<DOC>
	<DOCNO>NCT02812030</DOCNO>
	<brief_summary>Diabetic retinopathy remain leading cause blindness patient work age Western World , global epidemic diabetes . The recommended treatment diabetic retinopathy involve injection anti-vascular endothelial growth factor ( anti-VEGF ) eye . Based two recent clinical trial take place United States , Europe , Japan , Australia , NICE issue guidance July 2015 recommend aflibercept ( particular type anti-VEGF treatment ) available NHS patient central retina eye least 400 micrometres thick treatment . Real-world data differ significantly clinical trial data , therefore important evaluate impact aflibercept real world setting , particularly respect systemic control , patient poor systemic control exclude clinical trial . This study aim demonstrate efficacy aflibercept real-world setting , compare clinical trial setting .</brief_summary>
	<brief_title>Aflibercept Retinopathy Real World</brief_title>
	<detailed_description>Participants receive treatment usual diabetic macular oedema Bristol Eye Hospital ( University Hospitals Bristol NHS Foundation Trust ) Gloucestershire Hospitals NHS Foundation Trust . This entail injection aflibercept eye , initially four monthly dos , require regular monthly assessment . Additionally , patient invite complete standardise visual functioning questionnaire baseline roughly 6 12 month . Patients follow one year study , treatment continue necessary beyond end study . The primary outcome Best-Corrected Visual Acuity ( BCVA ) assess one year compare treatment arm two recent phase 3 RCTs ( VISTA VIVID ) . Additional secondary outcome retinal thickness , visual functioning , adverse event also collect . Real world data collect Bristol Eye Hospital Gloucestershire Hospitals NHS Foundation Trust . Bristol Eye Hospital , part RENOIR HIT , set hub speak outreach model treat patient diabetic macular oedema , service run since September 2013 . Treatment perform one three outreach site : South Bristol Community hospital , St Georges medical practice Worle , mobile macular unit currently base Cribbs Causeway . There three five new patient per month commence treatment aflibercept Bristol area . In Gloucestershire , treatment perform Cheltenham General Hospital , Gloucester Royal Hospital ; expect additional two three new patient per month site . All patient attend routine treatment invite take part study . In order detect clinically significant difference 5 letter use Early Treatment Diabetic Retinopathy Study ( ETDRS ) protocol , real world clinical trial , sample size calculation suggest need least 30 new patient compare treatment arm clinical trial .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>Aged 18+ year Eligible NHS treatment auspex Bristol Eye Hospital ( 3 outreach location ) Gloucestershire NHS Foundation trust . Diagnosis centreinvolving diabetic macular oedema Receiving first ever treatment aflibercept new eye Any previous antivascular endothelial growth factor ( antiVEGF ) treatment study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Observational Study</keyword>
	<keyword>aflibercept</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Visual Acuity</keyword>
</DOC>